One of the leading biopharma companies grounded in its commitment to advance medical care, improve patient outcomes and provide access to medicines that are safe, effective, and affordable.
- Expanding coverage of it’s hepatitis and respiratory brands in the emerging space of Community Health Center and county hospitals in China
- Loss of sales due to inability in covering doctors in Tier-1 cities (smaller cities) which are vastly spread across in China
- Reduced marketing budgets and increase in costs to deploy healthcare representatives in Tier 1 & 2 hospitals of Tier 1 cities
We developed NEXT Regulatory Submissions Planning – a web-based integrated planning platform, which enables the client to create, review, edit, and monitor submission plans across products and markets.
The single dashboard tool helps GRA group and bundle opportunities, manage capacity, plan and track better.
NEXT Regulatory Submissions Planning, a co-innovation by us and the client, is an industry-first regulatory planning platform that makes submissions fast and seamless.
The client is able to scale submissions from 700 in 11 markets to 35,389 across 51 markets within a year.
They save over 40,000 hours/year in regulatory operations, with projected savings of $1.03 million/year.
They can now bundle submissions to significantly reduce costs and prepare themselves to scale dossier submissions in future.